Datapoint: Merck-Seagen Deal Could Be in the Works

Merck & Co. is reportedly eyeing a $30 billion deal to acquire Seagen Inc., according to the Wall Street Journal. Merck already owns five million shares in the company. According to data from Evaluate Pharma, Seagen’s leading drug is Padcev, an antibody-drug conjugate made in partnership with Astellas. The drug is approved for the treatment of bladder cancer, where it holds covered or better status for 59% of all insured lives under the pharmacy benefit, and 81% of all insured lives under the medical benefit.

SOURCE: MMIT Analytics, as of 6/20/22, and Evaluate Pharma.

0 Comments
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
June 23

Datapoint: Skyrizi Scores Crohn’s Disease Nod

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
June 21

Datapoint: Centene Settles New Mexico Medicaid Dispute

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
June 20

Datapoint: Humana Rebrands Pharmacy Business

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today